Patents Examined by Christopher Yaen
-
Patent number: 7521540Abstract: Polynucleotides encoding mammalian ECM signaling molecules affecting the cell adhesion, migration, and proliferation activities characterizing such complex biological processes as angiogenesis, chondrogenesis, and oncogenesis, are provided. The polynucleotide compositions include DNAs and RNAs comprising part, or all, of an ECM signaling molecule coding sequence, or biological equivalents. Polypeptide compositions are also provided. The polypeptide compositions comprise mammalian ECM signaling molecules, peptide fragments, inhibitory peptides capable of interacting with receptors for ECM signaling molecules, and antibody products recognizing Cyr61. Also provided are methods for producing mammalian ECM signaling molecules.Type: GrantFiled: January 31, 2001Date of Patent: April 21, 2009Assignee: Munin CorporationInventors: Lester F. Lau, Cho-Yau Yeung, Jeffrey A. Greenspan
-
Patent number: 7449557Abstract: The present invention relates to complexes of alpha (2) macroglobulin associated with antigenic molecules for use in immunotherapy. The invention relates to methods for using such compositions in the diagnosis and treatment of immune disorders, proliferative disorders, and infectious diseases.Type: GrantFiled: June 4, 2001Date of Patent: November 11, 2008Assignee: University of Connecticut Health CenterInventors: Pramod K. Srivastava, Robert J. Binder
-
Patent number: 7420032Abstract: Disclosed are methods for obtaining at least one epitope suitable for detecting the presence of an antibody against a tumor associated antigen of a cancer in a sample. Kits, assays, and substrates employing the epitopes of the present invention are disclosed. Also disclosed are epitopes of NY-ESO-1 and XAGE-1b and methods of using thereof.Type: GrantFiled: May 19, 2005Date of Patent: September 2, 2008Assignees: The Regents of the University of California, National Institutes of HealthInventor: Gang Zeng
-
Patent number: 7410756Abstract: Featured are methods of modulating angiogenesis, e.g., by modulating PKC delta. The methods are useful in the treatment of disorders characterized by aberrant and/or increased blood vessel formation and/or increased permeability. The methods are also useful for treatment a disorder characterized by abnormal, inadequate or unstable blood vessel formation or increased permeability. Also featured are diagnostic and screening methods.Type: GrantFiled: June 17, 2003Date of Patent: August 12, 2008Assignee: Joslin Diabetes Center, Inc.Inventor: George L. King
-
Patent number: 7405060Abstract: The present invention provides multivalent vaccines for the treatment of B-cell malignancies (e.g., lymphomas and leukemias). The present invention also provides methods for the production of custom vaccines, including multivalent vaccines for the treatment of immune cell tumors malignancies as well as methods of treating immune cell tumors using custom vaccines.Type: GrantFiled: August 9, 2001Date of Patent: July 29, 2008Assignee: Genitope CorporationInventor: Dan W. Denney, Jr.
-
Patent number: 7402660Abstract: To gain a better understanding of tumor angiogenesis, new techniques for isolating endothelial cells (ECs) and evaluating gene expression patterns were developed. When transcripts from ECs derived from normal and malignant colorectal tissues were compared with transcripts from non-endothelial cells, over 170 genes predominantly expressed in the endothelium were identified. Comparison between normal- and tumor-derived endothelium revealed 79 differentially expressed genes, including 46 that were specifically elevated in tumor-associated endothelium. Experiments with representative genes from this group demonstrated that most were similarly expressed in the endothelium of primary lung, breast, brain, and pancreatic cancers as well as in metastatic lesions of the liver. These results demonstrate that neoplastic and normal endothelium in humans are distinct at the molecular level, and have significant implications for the development of anti-angiogenic therapies in the future.Type: GrantFiled: August 1, 2001Date of Patent: July 22, 2008Assignee: The Johns Hopkins UniversityInventors: Brad St. Croix, Bert Vogelstein, Kenneth W. Kinzler
-
Patent number: 7402306Abstract: The present invention relates to improved semi-allogeneic immunogenic cells which act to stimulate and induce an immunological response when administered to an individual. In particular, it relates to cells which express both allogeneic and syngeneic MHC determinants and which also express at least one antigen recognized by T lymphocytes. The invention is also directed to methods of inducing an immune response and methods of treating tumors by administering the semi-allogeneic immunogenic cells to an individual.Type: GrantFiled: March 10, 2000Date of Patent: July 22, 2008Assignee: The Board of Trustees of the University of IllinoisInventor: Edward P. Cohen
-
Patent number: 7396681Abstract: The invention relates to the use of Hsp70 protein or fragments thereof for the activation of NK-cells, pharmaceutical preparations, medical product or medical adjuvants containing a Hsp70 protein or fragments thereof or activated cells, method for the activation of NK-cells as well as medical use of the products obtained by the method of the invention.Type: GrantFiled: March 29, 1999Date of Patent: July 8, 2008Inventor: Gabriele Multhoff
-
Patent number: 7396920Abstract: A human protein (designated Carboxy-terminal Modulating protein, CTMP) is described and is identified as having tumour suppressor properties. CTMP has been shown to interact with protein kinase B and inhibit protein kinase B activity, establishing its importance in the protein kinase B signalling pathway.Type: GrantFiled: June 7, 2001Date of Patent: July 8, 2008Assignee: Novartis Forschungsstiftung Zweigniederlassung Friedrich Miescher Institute for Biomedical ResearchInventors: Brian A Hemmings, Sauveur-Michel Maira
-
Patent number: 7390871Abstract: A tumor antigen that comprises, as an active ingredient, a product of the Wilms' tumor suppressor gene WT1 or a peptide composed of 7-30 contiguous amino acids containing an anchor amino acid for binding to major histocompatibility complex (MHC) class I in said amino acid sequence, and a vaccine comprising said antigen.Type: GrantFiled: August 4, 2005Date of Patent: June 24, 2008Assignee: International Institute of Cancer Immunology, Inc.Inventors: Haruo Sugiyama, Yoshihiro Oka
-
Patent number: 7390882Abstract: The present invention is directed to compositions of matter useful for the diagnosis and treatment of tumor in mammals and to methods of using those compositions of matter for the same.Type: GrantFiled: October 11, 2005Date of Patent: June 24, 2008Assignee: Genentech, Inc.Inventors: Belinda Cairns, Gretchen Frantz, Hartmut Koeppen, Paul Polakis, Thomas D. Wu, Zemin Zhang
-
Patent number: 7388088Abstract: This invention provides for novel human antibodies that specifically bind to c-erbB-2. The antibodies may be used alone or as components of chimeric molecules that specifically target and deliver effector molecules to cells overexpressing c-erbB-2.Type: GrantFiled: March 5, 2002Date of Patent: June 17, 2008Assignee: The Regents of the University of CaliforniaInventors: James D. Marks, Robert Schier
-
Patent number: 7381799Abstract: The present invention provides a treatment for mammalian diseases characterized by pathological angiogenesis. The treatment consists of administering therapeutically active dosages of peptides containing specific amino acid sequences or antibodies that bind to cell membrane antigens on the surface of rapidly dividing endothelial cells.Type: GrantFiled: March 23, 2004Date of Patent: June 3, 2008Assignee: Ergon Pharmaceuticals LLCInventor: Adonia E. Papathanassiu
-
Patent number: 7375192Abstract: The present invention relates to antibodies and related molecules that specifically bind to CK-B4. Such antibodies have uses, for example, in the prevention and treatment of cancer as well as immune system diseases and disorders including cancers, as well as immune system diseases and disorders including autoimmune diseases, inflammatory disorders, immunodeficiencies, infections, HIV, arthritis, allergy, psoriasis, dermatitis, and inflammatory bowel disease. The invention also relates to nucleic acid molecules encoding anti-CK-B4 antibodies, vectors and host cells containing these nucleic acids, and methods for producing the same.Type: GrantFiled: April 30, 2003Date of Patent: May 20, 2008Assignee: Human Genome Sciences, Inc.Inventors: Craig A. Rosen, Steven M. Ruben
-
Patent number: 7364726Abstract: This invention comprises cellular vaccines and methods of using them in cancer immunotherapy, particularly in humans. The vaccines comprise a source of tumor-associated antigen, and a cytokine-secreting cell line. Tumor antigen may be provided in the form of primary tumor cells, tumor cell lines or tumor extracts prepared from the subject. In certain embodiments of the invention, the cytokine-secreting line is a separate tumor line that is allogeneic to the patient and genetically altered so as to produce a cytokine at an elevated level. Exemplary cytokines are IL-4, GM-CSF, IL-2, TNF-?, and M-CSF in the secreted or membrane-bound form. In these embodiments, the cytokine-producing cells provide immunostimulation in trans to generate a specific immune response against the tumor antigen.Type: GrantFiled: June 5, 2001Date of Patent: April 29, 2008Assignee: The Regents of the University of CaliforniaInventors: John C. Hiserodt, Martin R. Graf, Gale A. Granger
-
Patent number: 7361332Abstract: This invention provides methods and compositions for treating tumors. The cell population is made up of alloactivated lymphocytes from the patient or from one or more third-party donors that are alloactivated in a mixed lymphocyte culture. It can be placed into the tumor bed, or combined with tumor-associated antigen for administration to a distal site as a vaccine. The compositions recruit activated participation of the host Immune system, which then reacts against the tumor and provides a level of ongoing protection. Employing multiple third party donor cells confers particular advantages in terms of effectiveness, timing, and ease of use.Type: GrantFiled: January 26, 2001Date of Patent: April 22, 2008Assignee: The Regents of the University of CaliforniaInventors: Gale Arthur Granger, John C. Hiserodt, James Thompson
-
Patent number: 7361730Abstract: This invention relates, e.g., to colligin/Hsp47 molecules which are expressed on the surface of carcinoma cells and to the use of such expressed molecules as targets for, e.g., therapeutic agents or imaging agents. The invention also relates to peptides which bind specifically to external domains of such surface-localized Hsp47 molecules.Type: GrantFiled: March 15, 2000Date of Patent: April 22, 2008Assignee: University of MarylandInventor: John J. Sauk
-
Patent number: 7358351Abstract: To gain a better understanding of tumor angiogenesis, new techniques for isolating endothelial cells (ECs) and evaluating gene expression patterns were developed. When transcripts from ECs derived from normal and malignant colorectal tissues were compared with transcripts from non-endothelial cells, over 170 genes predominantly expressed in the endothelium were identified. Comparison between normal- and tumor-derived endothelium revealed 79 differentially expressed genes, including 46 that were specifically elevated in tumor-associated endothelium. Experiments with representative genes from this group demonstrated that most were similarly expressed in the endothelium of primary lung, breast, brain, and pancreatic cancers as well as in metastatic lesions of the liver. These results demonstrate that neoplastic and normal endothelium in humans are distinct at the molecular level, and have significant implications for the development of anti-angiogenic therapies in the future.Type: GrantFiled: November 3, 2004Date of Patent: April 15, 2008Assignee: The Johns Hopkins UniversityInventors: Brad St. Croix, Bert Vogelstein, Kenneth W. Kinzler
-
Patent number: 7354713Abstract: The present invention provides that ERR? is both a breast cancer biomarker and a breast cancer treatment target. A high ERR? level in breast cancer cells indicates good prognosis. A high level of ERR? in breast tissue suspected of being cancerous is indicative of breast cancer. Analyzing ERR? status and optionally along with the status of ER? can help breast cancer patients make treatment choices. Furthermore, breast cancer can be treated by decreasing ERR? activity in breast cancer cells.Type: GrantFiled: September 3, 2003Date of Patent: April 8, 2008Assignee: Wisconsin Alumni Research FoundationInventors: Janet E. Mertz, Eric Anthony Ariazi
-
Patent number: 7338658Abstract: Chimeric antibodies specific to human CD4 antigen, DNA encoding, pharmaceutical compositions containing and use thereof as therapeutic agents are taught. These chimeric antibodies contain Old World monkey variable sequences and human constant domain sequences, preferably human gamma 1, gamma 4 or mutated forms thereof. These antibodies possess desirable therapeutic properties including low antigenicity, reduced (or absent) T cell depleting activity, good affinity to human CD4 and enhanced stability (in vivo half-life).Type: GrantFiled: August 5, 2002Date of Patent: March 4, 2008Assignee: Biogen Idec Inc.Inventors: Nabil Hanna, Roland Anthony Newman, Mitchell Elliot Reff